Antares Pharma, Inc. (NASDAQ:ATRS) – Jefferies Group increased their FY2019 earnings per share estimates for shares of Antares Pharma in a report issued on Tuesday. Jefferies Group analyst A. Petrone now forecasts that the specialty pharmaceutical company will post earnings of $0.05 per share for the year, up from their previous forecast of $0.04. Jefferies Group also issued estimates for Antares Pharma’s FY2020 earnings at $0.21 EPS.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 40.24% and a negative net margin of 34.27%. The firm had revenue of $13.42 million for the quarter, compared to the consensus estimate of $12.99 million.

WARNING: “Jefferies Group Analysts Raise Earnings Estimates for Antares Pharma, Inc. (ATRS)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/jefferies-group-analysts-raise-earnings-estimates-for-antares-pharma-inc-atrs/1468682.html.

Other equities analysts have also recently issued research reports about the company. Vetr upgraded Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. Chardan Capital started coverage on Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. started coverage on Antares Pharma in a research report on Thursday, April 20th. They issued a “strong-buy” rating and a $4.30 price target on the stock. One analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $3.83.

Shares of Antares Pharma (ATRS) traded down 2.00% during mid-day trading on Thursday, hitting $2.94. The stock had a trading volume of 813,678 shares. The firm has a 50 day moving average price of $3.15 and a 200 day moving average price of $2.76. Antares Pharma has a 52-week low of $1.01 and a 52-week high of $3.37. The firm’s market cap is $458.42 million.

In related news, insider Fred M. Powell purchased 130,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were purchased at an average price of $2.79 per share, for a total transaction of $362,700.00. Following the transaction, the insider now directly owns 331,434 shares of the company’s stock, valued at approximately $924,700.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 11.60% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. bought a new position in shares of Antares Pharma during the second quarter valued at about $119,000. Legal & General Group Plc bought a new position in shares of Antares Pharma during the second quarter valued at about $120,000. Credit Suisse AG bought a new position in shares of Antares Pharma during the first quarter valued at about $146,000. National Planning Corp boosted its position in shares of Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the period. Finally, KCG Holdings Inc. boosted its position in shares of Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the period. Hedge funds and other institutional investors own 31.70% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.